Drug ‘significantly’ slows Alzheimer’s progression: Study A clinical trial of donanemab has now been peer reviewed and published, indicating it can decelerate decline in the disease’s early stages.
Meta-analysis shows social interaction reduces dementia risk Strong social connections were associated with a lower risk of mild cognitive impairment, dementia and death.
Next steps for new Alzheimer’s treatment Approved this month in the US, Alzheimer’s disease treatment lecanemab is yet to undergo the regulatory approval process in Australia.
Does nose picking lead to dementia? Researchers Dr Joyce Siette and Professor Mark Patrick Taylor analyse a recent study that has generated a lot of media interest.
New Alzheimer’s medication found to slow cognitive decline The drug may be available as early as 2023, but there are still hurdles to cross, write Bernadette McGuinness and Elizabeth Coulthard.
Controversial Alzheimer’s drug under TGA review ‘should not be approved’ Patients will be put at risk and taxpayers will face a significant economic burden if aducanumab receives regulatory approval, experts say.
Study links mental disorders early in life to dementia Mental health disorders are often an underappreciated category of modifiable risk factors for dementia, new research suggests.
Subsidised scan seeks to ensure more accurate Alzheimer’s diagnosis Positron emission tomography scans have been added to the MBS, but GP Professor Dimity Pond says further guidance is needed.
New blood test shows promise for Alzheimer’s disease diagnosis A simple test that detects proteins present in the brains of Alzheimer’s patients is coming to Australia.
Researchers uncover alternate theory for Alzheimer’s disease Rather than tangles and plaques being the cause of the disease, researchers are exploring the issue of lysosomal storage.